

IAP12 Rec'd PCT/PTO 25 AUG 2006

Docket No. 294685US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Rob HOOFT VAN HUIJSDUIJNEN, et al.

SERIAL NO: New U.S PCT Application Based on PCT/EP05/50823

GAU:

FILED: Herewith

EXAMINER:

FOR: USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Richard L. Treanor

Registration No. 36,379

Surinder Sachar
Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 294685US0PCT		SERIAL NO. 10/590808	
LIST OF REFERENCES CITED BY APPLICANT				New U.S PCT Application Based on PCT/EP05/50823			
				APPLICANT Rob HOOFT VAN HUIJSDUIJNEN, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AB						
	AC						
	AD						
	AE						
	AF						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AG	03/064376	08/07/03	WO			NO
	AH	101 17 823	10/17/02	DE(equivalent of US 2004/220411)			NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AO	JESSUP, Mariell et al., "Medical Progress Heart Failure", The New England Journal of Medicine, Vol. 348, No. 20, Pages 2007- 2018, May 15, 2003.					
	AP	HUNT, Sharon A. et al., "ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary", Journal of the American College of Cardiology, Vol. 38, No. 7, Pages 2101-2113, 2001					
	AQ	RADOMSKI, M. W. et al., "The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide", Br. J. Pharmac, Vol. 92, pages 639-646, 1987.					
	AR	ROSS, Russell, "The pathogenesis of atherosclerosis: a perspective for the 1990s", Nature, Vol. 362, Pages 801-809, April 29, 1993.					
	AS	SUWAIDI, Jassim Al et al., "Long-Term Follow-UP of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction", Circulation, Vol. 101, Pages 948-954, 2000.					
	AT	SCHAECHINGER, Volker et al., "Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease", Circulation, Vol. 101, Pages 1899-1906, 2000.					
	AU	PERTICONE, Francesco et al., "Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients", Circulation, Vol. 104, Pages 191-196, 2001.					
	AV	MCNAMARA, Dennis M. et al., "Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure", Circulation, Vol. 107, Pages 1598-1602, 2003.					
	AW	SCHERRER-CROSBIE, Marielle et al., "Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice", Circulation, Vol. 104, Pages 1286-1291, 2001.					
	AX	MOELLER, Niels Peter Hundahl et al., "Protein tyrosine phosphatases (PTPS) as drug targets: Inhibitors of PTP-1B for the treatment of diabetes", Current Opinion in Drug Discovery & Development, Vol. 3, No. 5, Pages 527-540, 2000.					
	AY	CHIN, Bernard SP et al., "New pharmacological strategies for the treatment of heart failure", Current Opinion in Investigational Drugs, Vol. 2, No. 7, Pages 923-928, 2001.					
	AZ	VARIN, Remi et al., "Exercise Improves Flow-Mediated Vasodilatation of Skeletal Muscle Arteries in Rats With Chronic heart Failure Role of Nitric Oxide, Prostanoids, and Oxidant Stress", Circulation, Vol. 99, Pages 2951-2957, 1999.					<input type="checkbox"/> Additional References sheet(s) attached
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

IAP12 Rec'd PCT/PTO 25 AUG 2006

New U.S. PCT Application Based on PCT/EP05/50823

Rob HOOFT VAN HUIJSDUIJNEN, et al.

Docket No. 294685 US

STATEMENT OF RELEVANCY

- 1) References AG and AH have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AO-AZ are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.